使用促黄体生成素释放激素类似物的长效剂型治疗前列腺癌。
Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
作者信息
Giuliani L, Barreca T, Giberti C, Franceschini R, Martorana G, Brancadoro M T, Salvemini M, Rolandi E
出版信息
Eur Urol. 1986;12(6):390-4. doi: 10.1159/000472664.
Chronic administration of a depot form of D-Trp6 luteinizing hormone-releasing hormone (LH-RH), an LH-RH analogue (3 mg i.m. every 28 days for a mean period of 9.1 months), to 14 patients with locally extended or metastatic cancer of the prostate provided a good degree of disease control. After a slight and transient increase in gonadotropin secretion, the peptide induced a sharp and long-lasting inhibition of both gonadotropin and testosterone secretion, contemporaneously with clinical improvement and without any important side effects. These results are comparable to those recorded by others after daily administration of LH-RH analogues.
对14例局部进展期或转移性前列腺癌患者长期给予一种长效剂型的D-色氨酸6促黄体生成激素释放激素（LH-RH），即一种LH-RH类似物（每28天肌肉注射3毫克，平均疗程9.1个月），可实现较好程度的疾病控制。在促性腺激素分泌出现轻微短暂增加后，该肽诱导了促性腺激素和睾酮分泌的急剧且持久的抑制，同时伴有临床改善，且无任何严重副作用。这些结果与其他人每日给予LH-RH类似物后所记录的结果相当。
Zotero 插件